Skip to main content

Table 1 Published human clinical trials comparing outcomes following isolation of stem cells from bone marrow vs peripheral blood.

From: Role of stem cells in cancer therapy and cancer stem cells: a review

Authors

Type of cancer

No. of pats

RCT/CT

Conclusion

Storek et al [42]

Haematological malignancies

140

RCT

PBSC yields higher lymphocyte subset counts and is associated with fewer infections

Hernandez et al [43]

Haematological malignancies

12

RCT

No significant difference in T, B and NK lymphoid cells reconstitution but PBSC influence faster reconstitution of cytotoxic subsets (CD8+/HLADR+ and NK lymphoid cells)

Talmadge et al [18]

Intermediate and high grade non-Hodgkin's lymphoma

116

RCT

The CD4:CD8 and CD45RA:CD45RO ratios were higher in the PBSC group. Accelerated reconstitution of NK cell activity following PBSC compared to BM.

Oehler et al [115]

Chronic myeloid leukaemia

72

CT

No statistically significant difference in acute or chronic GVHD, OS and disease free survival.

Heldal et al [116]

Haematological malignancies

61

CT

Statistically significant enhanced graft versus leukemia effect in allo PBSC group

Couban et al [41]

Haematological malignancies

228

RCT

Faster haematological recovery and improved survival in PBSC but no difference in GVHD

Nucci et al [117]

Haematological malignancies

56

RCT

Shorter duration of neutropenia in PBSC group but higher incidence of extensive chronic GVHD

Powles et al [118]

Haematological malignancies

39

RCT

Faster haematopoietic and immune recovery in PBSC and no difference in GVHDand OS

Mahmoud et al [119]

Haematological malignancies

30

RCT

Faster haematopoietic reconstitution in PBSC group with no difference in GVHD

  1. Keys: RCT – Randomised Control Trial, CT – Controlled Trial, PBSC – Peripheral Blood Stem Cells, NK – Natural Killer, CD8, CD4, CD45RA & CD45RO – Different types of T Cells, HLA – Human Leucocyte Antigen, GVHD – Graft Vs Host Disease, OS – Overall Survival, Pats – Patients, No – Number.